# Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

> **NCT07089719** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 21 (estimated)

## Conditions studied

- Dyspnea Caused by 2019-nCoV

## Interventions

- **DRUG:** Bevacizumab Injection

## Key facts

- **NCT ID:** NCT07089719
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-07-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07089719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07089719, "Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07089719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*